Barclays Upgrades Celldex Rating#
Barclays has upgraded Celldex Therapeutics (NASDAQ:CLDX) from Underweight to Overweight, reflecting increased confidence in the company's future. The price target has also been raised from $24 to $45. Currently, the stock is trading at $34.55, having gained nearly 89% over the past year and sitting just 2% below its 52-week high of $35.29.
Positive Trial Enrollment#
The upgrade is largely based on the successful enrollment in the Phase 3 EMBARQ trial, which was completed six months ahead of schedule. This trial focuses on chronic spontaneous urticaria (CSU), a condition characterized by recurrent hives. Barclays noted that this faster enrollment indicates strong demand and enthusiasm for the treatment being tested, barzolvolimab.
Increased Confidence in Success Rates#
Barclays has raised its probability of success for the CSU treatment from 65% to 85%. Additionally, the firm has increased its revenue estimates for this treatment to $1.4 billion, up from $1.0 billion. For chronic inducible urticaria, another condition being targeted, the probability of success has been raised from 65% to 75%, with peak revenue estimates now at $541 million, up from $281 million.
Recent Developments#
In other news, Celldex recently completed a public offering, raising approximately $345 million by selling nearly 11.9 million shares at $29 each. This offering included additional shares purchased by underwriters. The company also shared promising Phase 2 trial data for barzolvolimab, which showed improvements in patients' quality of life, as presented at the American Academy of Dermatology Annual Meeting. These advancements highlight Celldex's commitment to developing effective treatments for skin conditions.